Scinai Immunotherapeutics Ltd. (SCNI) Cash Flow Statement
Scinai Immunotherapeutics Ltd. (SCNI) generated -$7.4M of operating cash flow over the twelve months to 2026-06-30, spent $127000 on capital expenditure and had free cash flow of -$7.5M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SCNIScinai Immunotherapeutics Ltd.Follow SCNI — free
—
Price chart with a free account
- Market cap
- 3.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- —
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -9.4 | -6.3 | -6.0 | -7.4 | |
| Capital expenditure | 0.6 | 0.0 | 0.0 | -0.1 | |
| Free cash flow | -10.0 | -6.3 | -6.1 | -7.5 | |
| Stock-based compensation | 1.1 | 0.7 | 0.3 | — |
USD millions · SEC XBRL
Scinai Immunotherapeutics Ltd. — questions
- What is Scinai Immunotherapeutics Ltd.'s operating cash flow?
- -$7.4M over the twelve months to 2026-06-30.
- How much does Scinai Immunotherapeutics Ltd. spend on capital expenditure?
- $127000 over the twelve months to 2026-06-30.
- What is Scinai Immunotherapeutics Ltd.'s free cash flow?
- -$7.5M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Scinai Immunotherapeutics Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.